BNP Paribas Financial Markets’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-30,498
| Closed | -$104K | – | 4512 |
|
|
2018
Q3 | $104K | Buy |
30,498
+151
| +0.5% | +$544 | ﹤0.01% | 2722 |
|
|
2018
Q2 | $114K | Buy |
30,347
+7,974
| +36% | +$38.8K | ﹤0.01% | 2721 |
|
|
2018
Q1 | $91.5K | Buy |
22,373
+772
| +4% | +$3.6K | ﹤0.01% | 3231 |
|
|
2017
Q4 | $100K | Buy |
21,601
+11,998
| +125% | +$66.1K | ﹤0.01% | 3303 |
|
|
2017
Q3 | $68.2K | Sell |
9,603
-549
| -5% | -$3.95K | ﹤0.01% | 2985 |
|
|
2017
Q2 | $73.4K | Buy |
10,152
+8,514
| +520% | +$53.2K | ﹤0.01% | 2981 |
|
|
2017
Q1 | $10.1K | Sell |
1,638
-3,999
| -71% | -$21.9K | ﹤0.01% | 3173 |
|
|
2016
Q4 | $33K | Sell |
5,637
-1,089
| -16% | -$5.95K | ﹤0.01% | 3004 |
|
|
2016
Q3 | $35.7K | Buy |
6,726
+3,693
| +122% | +$19.9K | ﹤0.01% | 2585 |
|
|
2016
Q2 | $20.1K | Buy |
+3,033
| New | +$17K | ﹤0.01% | 2586 |
|
|
2016
Q1 | – | Sell |
-23,664
| Closed | -$120K | – | 3356 |
|
|
2015
Q4 | $120K | Buy |
23,664
+2,244
| +10% | +$10.7K | ﹤0.01% | 2215 |
|
|
2015
Q3 | $75.4K | Buy |
21,420
+12,802
| +149% | +$85.7K | ﹤0.01% | 2572 |
|
|
2015
Q2 | $86K | Buy |
8,618
+6,624
| +332% | +$71K | ﹤0.01% | 2159 |
|
|
2015
Q1 | $25.4K | Buy |
+1,994
| New | +$25.6K | ﹤0.01% | 2254 |
|
|
2014
Q4 | – | Sell |
-6,041
| Closed | -$83.1K | – | 3667 |
|
|
2014
Q3 | $83.1K | Buy |
6,041
+5,785
| +2,260% | +$88.6K | ﹤0.01% | 2306 |
|
|
2014
Q2 | $3.94K | Buy |
256
+136
| +113% | +$1.93K | ﹤0.01% | 2717 |
|
|
2014
Q1 | $1.77K | Sell |
120
-940
| -89% | -$14.2K | ﹤0.01% | 2697 |
|
|
2013
Q4 | $13.7K | Sell |
1,060
-21,469
| -95% | -$256K | ﹤0.01% | 2445 |
|
|
2013
Q3 | $227K | Sell |
22,529
-6,453
| -22% | -$57.4K | ﹤0.01% | 2144 |
|
|
2013
Q2 | $216K | Buy |
+28,982
| New | +$226K | ﹤0.01% | 2261 |
|
BNP Paribas Financial Markets's KERX Position: Q4 2018 in Review
BNP Paribas Financial Markets sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 30,498 shares — an estimated $104K sold.
BNP Paribas Financial Markets first reported a position in KERX in Q2 2013 and held it in 20 quarters. The position peaked at $227K in Q3 2013. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- BNP Paribas Financial Markets reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- BNP Paribas Financial Markets sold 30,498 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $104K.
- BNP Paribas Financial Markets first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 20 quarters.
- BNP Paribas Financial Markets's Keryx Biopharmaceuticals Inc position peaked at $227K in Q3 2013.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2018, filed 12 Feb 2019.